polycystic liver disease
Conditions
Interventions
The patients will be randomized to either the octreotide or the lanreotide
group and will receive every 28 days for 24 weeks octreotide 60 mg or
lanreotide 120 mg, respectively.
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - patients with polycystic liver disease - at least 18 years of age - Informed consent, patients are willing and able to comply with the study drug regimen and all other study requirements
Exclusion criteria
Exclusion criteria: - kidney transplantation - renal failure requiring hemodialysis - use of oral contraceptives or estrogen suppletion - women who are pregnant or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in liver volume from baseline to 24 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in kidney volume from baseline to 24 weeks, change in symptoms from baseline to 24 weeks, change in quality of life from baseline to 24 weeks, proportion of patients that have any reduction of liver volume at 24 weeks, and adverse events during the 24 weeks. | — |
Countries
Netherlands
Outcome results
None listed